Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

450
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
450
Autoimmune Disorders01:29

Autoimmune Disorders

431
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
431
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
127
Hypersensitivities01:30

Hypersensitivities

633
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
633
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

907
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
907
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

163
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
163

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The future of splenic elastography: Is it a valuable tool for personalized treatment?

Revista de gastroenterologia de Mexico (English)·2026
Same author

Implementation of ambulatory health care quality standards in an Occupational Mutual Insurance Company.

Journal of healthcare quality research·2026
Same author

Frailty and food intake quality in patients with chronic hepatitis C virus (HCV) infection with or without cirrhosis.

Revista de gastroenterologia de Mexico (English)·2026
Same author

The Fifth Mexican consensus on the diagnosis and treatment of Helicobacter pylori infection.

Revista de gastroenterologia de Mexico (English)·2025
Same author

Response to Pérez-Nieto et al., "Considerations about the balanced crystalloid solution recommendation in acute variceal bleeding".

Revista de gastroenterologia de Mexico (English)·2025
Same author

First daily carboplatin desensitization protocol in a child: A case report.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology·2025

相关实验视频

Updated: Jun 30, 2025

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.0K

免疫媒介性肝炎:基本概念和治疗方法

J A Velarde-Ruiz Velasco1, D K Tapia Calderón2, S Cerpa-Cruz3

  • 1Servicio de Gastroenterología, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico; Departamento de Clínicas Médicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.

Revista de gastroenterologia de Mexico (English)
|March 14, 2024
PubMed
概括
此摘要是机器生成的。

免疫媒介性肝炎 (IMH) 是免疫检查点抑制剂 (ICI) 癌症治疗的一个不良事件. 本综述详细介绍了IMH流行病学,诊断,危险因素和管理,包括肝细胞癌.

关键词:
迪利迪利 (DILI) 是一个词.药物引起的肝损伤 (DILI)肝炎是一种免疫媒介.免疫检查点抑制剂 免疫检查点抑制剂免疫媒介性肝炎是一种免疫媒介性肝炎.免疫治疗是一种免疫疗法.免疫控制点抑制剂 免疫控制点抑制剂免疫疗法是一种免疫疗法.这是一个治疗方法.治疗方法 治疗方法

更多相关视频

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

19.2K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.9K

相关实验视频

Last Updated: Jun 30, 2025

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.0K
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

19.2K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.9K

科学领域:

  • 肝病学 肝病学是一种肝病学.
  • 在瘤学瘤学.
  • 免疫学 免疫学 免疫学

背景情况:

  • 免疫检查点抑制剂 (ICI) 已经改变了先进的癌症治疗.
  • 增加ICI的使用导致了更多的免疫媒介不良事件,特别是影响肝脏.
  • 免疫媒介性肝炎 (IMH) 是接受免疫治疗的患者的一个重大问题.

研究的目的:

  • 在癌症免疫治疗的背景下,提供免疫媒介性肝炎 (IMH) 的最新审查.
  • 涵盖IMH的流行病学,诊断,风险因素和进展.
  • 讨论各种癌症的IMH发病率,并概述当前的治疗指南.

主要方法:

  • 关于免疫媒介性肝炎的最新研究的文献综述.
  • 对流行病学数据,临床特征和风险因素的分析.
  • 综合当前的诊断标准和治疗建议.

主要成果:

  • IMH的发病率各不相同,从轻微的转氨酶升高到严重的肝炎.
  • 越来越多的IMH风险因素和临床模式正在被阐明.
  • 管理策略正在根据临床表现和癌症类型,包括肝细胞癌,不断发展.

结论:

  • 在接受免疫治疗的患者中,IMH 是一个关键考虑因素.
  • 早期诊断和适当的管理对于减轻严重后果至关重要.
  • 需要进一步的研究来优化治疗方案,并改善IMH患者的治疗结果.